Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2025

Original Article

Comparison of IL-23 versus IL-17 inhibitors for new-onset psoriatic arthritis in patients with psoriasis

Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Citation & Authors

BioDrugs. 2025;39(2):297-306.

Sebastian Yu; An-Ping Huo; Yu-Hsun Wang; James Cheng-Chung Wei

ABSTRACT · CHINESE TRANSLATION

Translated abstract

Translated from the licensed abstract via the Chinese version. This is not an official journal translation.

background

Psoriatic arthritis (PsA) is a common comorbidity of psoriasis (PsO) and imposes a substantial disease burden. Biologics targeting the IL-23/IL-17 axis are widely used for psoriasis, but their relative effectiveness in preventing PsA remains unclear.

purpose

To compare incident PsA in patients with psoriasis receiving IL-23 versus IL-17 inhibitors.

method

This retrospective cohort study used real-world data from 53 healthcare organizations in the TriNetX US Collaborative Network to identify adults with psoriasis receiving either drug class between January 2019 and June 2022. Cox regression assessed PsA risk, reporting HRs and 95% confidence intervals, with subgroup analyses by age, sex, and race/ethnicity. Sensitivity analyses additionally compared TNF inhibitors to assess robustness.

result

Among 4,580 patients, 2,273 received IL-23 inhibitors and 2,307 received IL-17 inhibitors. IL-23 inhibitors were significantly associated with a lower risk of incident PsA (HR 0.60; 95% CI 0.44–0.82; P=0.001), particularly in patients aged 41–65 years (0.42; 0.27–0.64; P<0.001) and women (0.57; 0.38–0.86; P=0.007). Risk was significantly lower in White patients (0.55; 0.38–0.79; P=0.001), but not in Black/African American patients (1.37; 0.37–5.13; P=0.637). Sensitivity analyses comparing TNF inhibitors supported the robustness of the findings.

Conclusion

Among patients with psoriasis, IL-23 inhibitors were associated with a lower risk of developing PsA than IL-17 inhibitors, particularly in certain age, sex, and racial/ethnic groups. These findings suggest that IL-23 inhibitors may be more suitable for patients at high risk of PsA and may inform future treatment guideline updates. Future studies should incorporate individual factors, including comorbidities, race/ethnicity, and genetic susceptibility, to refine biologic selection and clinical strategies for preventing PsA.

Original work: Author of the above paper. Source:Public Summary ↗. This translation is based on the Chinese rendering of the original English abstract.

Original work license:CC BY-NC ↗;Translations are subject to the same licensing conditions.